DOI QR코드

DOI QR Code

Selective miRNA Expression Profile in Chronic Myeloid Leukemia K562 Cell-derived Exosomes

  • Feng, Dan-Qin (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University) ;
  • Huang, Bo (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University) ;
  • Li, Jing (Department of Clinical Laboratory, the First Affiliated Hospital of Nanchang University) ;
  • Liu, Jing (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University) ;
  • Chen, Xi-Min (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University) ;
  • Xu, Yan-Mei (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University) ;
  • Chen, Xin (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University) ;
  • Zhang, Hai-Bin (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University) ;
  • Hu, Long-Hua (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University) ;
  • Wang, Xiao-Zhong (Department of Clinical Laboratory, the Second Affiliated Hospital of Nanchang University)
  • Published : 2013.12.31

Abstract

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hematopoietic stem cell scarrying the Philadelphia (Ph) chromosome and an oncogenic BCR-ABL1 fusion gene. The tyrosine kinase inhibitor (TKI) of BCR-ABL1 kinase is a treatment of choice for control of CML. Objective: Recent studies have demonstrated that miRNAs within exosomes from cancer cells play crucial roles in initiation and progression. This study was performed to assess miRNAs within exosomes of K562 cells. Methods: miRNA microarray analysis of K562 cells and K562 cell-derived exosomes was conducted with the 6th generation miRCURYTM LNA Array (v.16.0). Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were also carried out. GO terms and signaling pathways were categorized into 66 classes (including homophilic cell adhesion, negative regulation of apoptotic process, cell adhesion) and 26 signaling pathways (such as Wnt). Results: In exosomes, 49 miRNAs were up regulated as compared to K562 cells, and two of them were further confirmed by quantitative real-time PCR. There are differentially expressed miRNAs between K562 cell derived-exosomes and K562 cells. Conclusion: Selectively expressed miRNAs in exosomes may promote the development of CML via effects on interactions (e.g. adhesion) of CML cells with their microenvironment.

References

  1. Alikian M, Gerrard G, Subramanian PG, et al (2012). BCRABL1 kinase domain mutations: Methodology and clinical evaluation. Am J Hematol, 87, 298-304. https://doi.org/10.1002/ajh.22272
  2. Benetatos L, Hatzimichael E, Londin E, et al (2013). The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell Mol Life Sci, 70, 795-814. https://doi.org/10.1007/s00018-012-1080-8
  3. Chen HY, Lin YM, Chung HC, et al (2012). miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res, 72, 3631-41. https://doi.org/10.1158/0008-5472.CAN-12-0667
  4. Druker BJ, Guilhot F, O'Brien SG, et al (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med, 355, 2408-17. https://doi.org/10.1056/NEJMoa062867
  5. Ernst A, Hofmann S, Ahmadi R, et al (2009). Genomic and Expression Profiling of Glioblastoma Stem Cell-Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival. Clin Cancer Res, 15, 6541-50. https://doi.org/10.1158/1078-0432.CCR-09-0695
  6. Ernst T, Hochhaus A (2012). Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression. Semin Oncol, 39, 58-66. https://doi.org/10.1053/j.seminoncol.2011.11.002
  7. Fabbri M, Paone A, Calore F, et al (2012). MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A, 109, E2110-6. https://doi.org/10.1073/pnas.1209414109
  8. Fountzilas E, Kelly AD, Perez-Atayde AR, et al (2012). A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study. BMC Genomics, 13, 332. https://doi.org/10.1186/1471-2164-13-332
  9. Ge R, Tan E, Sharghi-Namini S, et al (2012). Exosomes in Cancer Microenvironment and Beyond: have we Overlooked these Extracellular Messengers? Cancer Microenviron, 5, 323-32. https://doi.org/10.1007/s12307-012-0110-2
  10. Gkretsi V, Zhang YJ, Tu YZ, et al (2005). Physical and functional association of migfilin with cell-cell adhesions. J Cell Sci, 118: 697-710. https://doi.org/10.1242/jcs.01638
  11. Henderson MC, Azorsa DO (2012). The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol, 2, 38.
  12. Hu G, Drescher KM, Chen XM (2012). Exosomal miRNAs: Biological Properties and Therapeutic Potential. Front Genet, 3, 56.
  13. Hu H, Li Y, Gu J, et al (2010). Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells. Leuk Lymphoma, 51, 694-701. https://doi.org/10.3109/10428191003596835
  14. Khan NI, Bradstock KF, Bendall LJ (2007). Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Brit J Haematol, 138, 338-48. https://doi.org/10.1111/j.1365-2141.2007.06667.x
  15. Kharaziha P, Ceder S, Li Q, et al (2012). Tumor cell-derived exosomes: A message in a bottle[J]. Biochim Biophys Acta, 1826, 103-11.
  16. Liu L, Chen R, Huang S, et al (2012). miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med Oncol, 29, 243-7. https://doi.org/10.1007/s12032-010-9807-6
  17. Mineo M, Garfield SH, Taverna S, et al (2012). Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion. Angiogenesis, 15, 33-45. https://doi.org/10.1007/s10456-011-9241-1
  18. Munich S, Sobo-Vujanovic A, Buchser WJ, et al (2012). Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology, 1, 1074-83. https://doi.org/10.4161/onci.20897
  19. O'Brien K, Rani S, Corcoran C, et al (2013). Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer, 49, 1845-59. https://doi.org/10.1016/j.ejca.2013.01.017
  20. Ohshima K, Inoue K, Fujiwara A, et al (2010). Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One, 5, e13247. https://doi.org/10.1371/journal.pone.0013247
  21. Pallasch CP, Patz M, Park YJ, et al (2009). miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood, 114, 3255-64. https://doi.org/10.1182/blood-2009-06-229898
  22. Patnaik SK, Kannisto E, Knudsen S, et al (2010). Evaluation of MicroRNA Expression Profiles That May Predict Recurrence of Localized Stage I Non-Small Cell Lung Cancer after Surgical Resection. Cancer Res, 70, 36-45. https://doi.org/10.1158/0008-5472.CAN-09-3153
  23. Peinado H, Aleckovic M, Lavotshkin S, et al (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med, 18, 883-91. https://doi.org/10.1038/nm.2753
  24. Rao Q, Wang J-Y, Meng J, et al (2011). Low-expression of E-cadherin in leukaemia cells causes loss of homophilic adhesion and promotes cell growth. Cell Biol Int, 35, 945-51. https://doi.org/10.1042/CBI20100456
  25. Roberson CD, Atay S, Gercel-Taylor C, et al (2010). Tumorderived exosomes as mediators of disease and potential diagnostic biomarkers. Cancer Biomark, 8, 281-91.
  26. Roccaro AM, Sacco A, Maiso P, et al (2013). BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest, 123, 1542-55. https://doi.org/10.1172/JCI66517
  27. Rokah OH, Granot G, Ovcharenko A, et al (2012). Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One, 7, e35501. https://doi.org/10.1371/journal.pone.0035501
  28. Savina A, Furlan M, Vidal M, et al (2003). Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem, 278, 20083-90. https://doi.org/10.1074/jbc.M301642200
  29. Tanaka M, Oikawa K, Takanashi M, et al (2009). Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients. PLoS One, 4, e5532. https://doi.org/10.1371/journal.pone.0005532
  30. Umezu T, Ohyashiki K, Kuroda M, et al (2013). Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene, 32, 2747-55. https://doi.org/10.1038/onc.2012.295
  31. Valadi H, Ekstrom K, Bossios A, et al (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol, 9, 654-9. https://doi.org/10.1038/ncb1596
  32. van Dommelen SM, Vader P, Lakhal S, et al (2012). Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery. J Control Release, 161, 635-44. https://doi.org/10.1016/j.jconrel.2011.11.021
  33. Vlassov AV, Magdaleno S, Setterquist R, et al (2012). Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta, 1820, 940-8. https://doi.org/10.1016/j.bbagen.2012.03.017
  34. Wahlgren J, Karlson Tde L, Glader P, et al (2012). Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. PLoS One, 7, e49723. https://doi.org/10.1371/journal.pone.0049723
  35. Wang W, Zhao L-J, Tan Y-X, et al (2012). MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis, 33, 1113-20. https://doi.org/10.1093/carcin/bgs113
  36. Weisberg E, Sattler M, Ewaniuk DS, et al (1997). Role of focal adhesion proteins in signal transduction and oncogenesis. Crit Rev Oncogen, 8, 343-58. https://doi.org/10.1615/CritRevOncog.v8.i4.40
  37. Willis TG, Zalcberg IR, Coignet LJA, et al (1998). Molecular cloning of translocation t (1;14) (q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood, 91, 1873-81.
  38. Xiong F, Wu C, Chang J, et al (2011). Genetic Variation in an miRNA-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung Cancer. Cancer Res, 71: 5175-81. https://doi.org/10.1158/0008-5472.CAN-10-4407
  39. Yang C, Robbins PD (2011). The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol, 2011, 842-9.
  40. Zimmerman EI, Dollins CM, Crawford M, et al (2010). Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol, 78, 811-7. https://doi.org/10.1124/mol.110.066258

Cited by

  1. Construction of a Protein-Protein Interaction Network for Chronic Myelocytic Leukemia and Pathway Prediction of Molecular Complexes vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5325
  2. Elevated Serum Ferritin Levels in Patients with Hematologic Malignancies vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6099
  3. MicroRNAs as Potential Biomarkers in Acute Promyelocytic Leukaemia vol.2014, pp.2090-8520, 2014, https://doi.org/10.1155/2014/932342
  4. The fusion of two worlds: Non-coding RNAs and extracellular vesicles - diagnostic and therapeutic implications (Review) vol.46, pp.1, 2014, https://doi.org/10.3892/ijo.2014.2712
  5. Deciphering the cross-talking of human competitive endogenous RNAs in K562 chronic myelogenous leukemia cell line vol.12, pp.12, 2016, https://doi.org/10.1039/C6MB00568C
  6. ATL-derived exosomes modulate mesenchymal stem cells: potential role in leukemia progression vol.13, pp.1, 2016, https://doi.org/10.1186/s12977-016-0307-4
  7. Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy vol.18, pp.6, 2017, https://doi.org/10.3390/ijms18061183
  8. Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a vol.2017, pp.1687-9678, 2017, https://doi.org/10.1155/2017/9012152
  9. Exosomes in cancer: small vesicular transporters for cancer progression and metastasis, biomarkers in cancer therapeutics vol.6, pp.2167-8359, 2018, https://doi.org/10.7717/peerj.4763